SGLT-2 Inhibitor

We consider SGLT-2 inhibitors to be a promising healthspan-promoting intervention due to their ability to improve metabolic health and reduce the risk of age-related diseases. By enhancing glucose excretion and improving insulin sensitivity, SGLT-2 inhibitors like Canagliflozin and Bexagliflozin effectively target factors contributing to metabolic syndrome—a key driver of aging and chronic disease progression. Canagliflozin and Bexagliflozin belong to a class of medications known as sodium-glucose cotransporter-2 (SGLT-2) inhibitors. These medications work by blocking the SGLT-2 protein in the kidneys, which is responsible for reabsorbing glucose from the urine back into the bloodstream.